Consensus Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
1.4 ^USD	+0.72%		-2.78%	-38.86%

Mar. 22	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director	CI

Evolution of the average Target Price on Checkpoint Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c6fa27681155935e5b1aa2.FdkjsGFFzhgfeJ1hatFwsfyD2L8g06HqzOP5VrHBffA.ULZB9BgW-X8mEvcxPoESw5uul9xYgemCu6DKMOW3NpJWj0XfCwuISGoi-g~76e8f723e219ce8fd0301107070ae071

Analyst Recommendations on Checkpoint Therapeutics, Inc.

B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	Dec. 20	MT
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	23-08-22	MT
Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	23-08-15	MT
Ladenburg Thalmann Adjusts Checkpoint Therapeutics' Price Target to $47 From $65, Keeps Buy Rating	23-08-15	MT
Cantor Fitzgerald Adjusts Checkpoint Therapeutics' Price Target to $14 From $19, Keeps Overweight Rating	23-08-15	MT
Lake Street Adjusts Checkpoint Therapeutics' Price Target to $16 From $22, Keeps Buy Rating	23-05-30	MT
Ladenburg Thalmann Lowers Price Target on Checkpoint Therapeutics to $65 From $69, Maintains Buy Rating	23-05-17	MT
Cantor Fitzgerald Cuts Price Target on Checkpoint Therapeutics to $19 From $54, Maintains Overweight Rating	23-05-16	MT
HC Wainwright Adjusts Price Target on Checkpoint Therapeutics to $34 From $76, Maintains Buy Rating	23-04-28	MT
Lake Street Adjusts Price Target on Checkpoint Therapeutics to $22 From $32, Maintains Buy Rating	23-04-04	MT
Ladenburg Thalmann Adjusts Checkpoint Therapeutics Price Target to $69 From $96, Maintains Buy Rating	23-04-03	MT
Lake Street Adjusts Price Target on Checkpoint Therapeutics to $41 From $70, Maintains Buy Rating	23-01-05	MT
HC Wainwright Adjusts Checkpoint Therapeutics' Price Target to $76 From $26, Keeps Buy Rating	22-12-23	MT
B. Riley Raises Checkpoint Therapeutics' Price Target to $15 From $7 Following Reverse Split, Equity Offering; Keeps Buy Rating	22-12-19	MT
B. Riley Resumes Checkpoint Therapeutics at Buy with $7 PT, Notes Focus on Cutaneous Squamous Cell Carcinoma Regulatory Approval Process Initiating by Year End 2022	22-07-14	MT
CORRECTION : Wedbush Adds Check Point Software Technologies to Best Ideas List, Maintains Outperform Rating, $145 Price Target	22-07-12	MT
Wedbush Raises Price Target for Checkpoint Therapeutics to $76 From $68, Maintains Outperform Rating, Adds to Best Ideas List	22-07-12	MT
HC Wainwright Adjusts Checkpoint Therapeutics' Price Target to $26 From $17, Maintains Buy Rating	22-01-25	MT
CHECKPOINT THERAPEUTICS : B. Riley Starts Checkpoint Therapeutics at Buy with $18 PT, Believes Potential of Lead Asset Cosibelimab Not Fully Appreciated	21-06-09	MT
CHECKPOINT THERAPEUTICS : Cantor Fitzgerald Starts Checkpoint Therapeutics at Overweight With $16 Price Target	21-01-20	MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage	18-08-02	RE